Clinical Trials
44 trialsA Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
LIMBER
Incyte Corporation
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Icahn School of Medicine at Mount Sinai
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
Herlev Hospital
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Roswell Park Cancer Institute
Study of Select Combinations in Adults With Myelofibrosis
Novartis
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Mayo Clinic
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
Icahn School of Medicine at Mount Sinai
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
Eli Lilly and Company
A Study in Myeloproliferative Disorders
Eli Lilly and Company
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
Eli Lilly and Company
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Indiana University
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Pyroxamide in Treating Patients With Advanced Cancer
Memorial Sloan Kettering Cancer Center
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
National Cancer Institute (NCI)
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
A Safety Study of XL019 in Adults With Myelofibrosis
Exelixis
Combination Chemotherapy in Treating Patients With Advanced Cancer
NYU Langone Health
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
University of Arizona
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Rutgers, The State University of New Jersey